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Abstract 26 
Objective. With improving rates of initial survival in severe sepsis, second-hit 27 
infections that occur following resolution of the primary insult carry an increasing 28 
burden of morbidity. However, despite the clinical relevance of these infections, no data 29 
are available on differential outcomes in patients with first and second-hit infections 30 
depending on the nature of the causative organism. This study aims to explore any 31 
differences in these subgroups. 32 
Design. In a retrospective, observational cohort study, the United Kingdom Intensive 33 
Care National Audit and Research Centre (ICNARC) database was used to explore the 34 
outcomes of patient with first-hit infections leading to sepsis, and sepsis patients with 35 
second-hit infections grouped according to the Gram status of the causative organism. 36 
Setting. General critical care units in England, Wales, and Northern Ireland 37 
participating in the ICNARC programme between 1 January 2007 – 30 June 2012.  38 
Patients. Patient groups analysed included 2119 patients with and 1319 patients without 39 
sepsis who developed an intensive care unit acquired infection in blood. Subgroups 40 
included patients with trauma, emergency neurosurgical, elective surgical, and 41 
cardiogenic shock. 42 
Measurements and main results. Gram-negative organisms were associated with 43 
poorer outcomes in first-hit infections. The 90-day mortality of patients who developed 44 
a Gram-negative infection was 43.6% following elective surgery and 27.9% following 45 
trauma. This compared with a mortality of 25.6% and 20.6%, respectively, in Gram-46 
positive infections. Unexpectedly, an inverse relationship between Gram status and 47 
mortality was observed in second-hit infections. Patients with an initial diagnosis of 48 
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sepsis who developed secondary infections caused by Gram-negative organisms had a 49 
90-day mortality of 40.4%, compared with 43.6% in Gram-positive infections. 50 
Conclusions. Our study identifies a fundamental difference in patient outcomes 51 
between first-hit and second-hit bacterial infections, which may be due to genetic, 52 
microbiological, immunological, and environmental factors. This finding has direct 53 
implications for risk stratification and defines future research priorities. 54 
 55 
Keywords: sepsis, bacterial infections, intensive care, Gram-positive bacterial 56 
infections, Gram-negative bacterial infections. 57 
 58 
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Introduction 60 
Measured using any chosen metric, sepsis is a devastating condition for patients, 61 
their families, and society as a whole (1,2). It accounts for 15-20% of all deaths in the 62 
developing world and kills over 1.5 million newborns and children every year (1,3). As 63 
a medical condition, it is more deadly than stroke, killing a third of all patients with the 64 
severe form of the illness (3,4). It is responsible for a third of admissions to the 65 
intensive care unit (ICU) and costs the economy of the United States alone $17 billion 66 
annually (4-6). For patients who do survive, many carry a substantial burden of 67 
continued physical and psychological ill health, with return to work rates below 65% 68 
(5,7). 69 
Large-scale surveillance studies have identified the most common organisms 70 
implicated in sepsis (8,9). Although fungal and viral infections contribute to many 71 
sepsis deaths, bacterial pathogens are the most frequent causative agents, with 72 
Staphylococcus aureus and Streptococcus pneumoniae representing the most relevant 73 
Gram-positive species, and Escherichia coli, Klebsiella spp., and Pseudomonas 74 
aeruginosa dominating the Gram-negative group (4,9). The relative contribution by 75 
each of these different organism types is heavily influenced by local population 76 
characteristics, organism virulence, and health care structure variables. 77 
The organism class responsible for the primary infection, has been shown to 78 
play a role in determining the mortality of patients with sepsis. In this study, these 79 
primary infections are termed “first-hit” infections. However, there are conflicting 80 
findings regarding the magnitude and the direction of the differences between Gram-81 
positive and Gram-negative infections (10-12). The largest of these studies (12), with 82 
over 5 million patient records in the United States analysed retrospectively, attributed a 83 
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mortality of 30.4% to sepsis caused by Gram-positive organisms and 23.3% to Gram-84 
negative organisms. However, the highest mortality in this cohort was 36.3% in patients 85 
infected with anaerobic Gram-negative microbes suggesting the importance of further 86 
stratification according to organism types instead of solely relying on Gram status.  87 
With improving rates of initial survival in severe sepsis (13-15), infections that 88 
occur following resolution of the initial insult carry an increasing burden of morbidity 89 
(13,15,16). In this study these infections are termed second-hit infections as opposed to 90 
first-hit infections that occur in patient’s without prior sepsis. Many low virulence 91 
nosocomial infections occur following resolution of the initial primary infective insult 92 
and include pathologies such as ventilator-associated pneumonia, intravascular line 93 
infections as well as reactivation of latent chronic viral infections such as 94 
cytomegalovirus (9).  However, despite the clinical relevance of these infections, there 95 
are no data available in the literature on differential outcomes from Gram-positive 96 
pathogens compared with Gram-negative species in patients with first and second-hit 97 
infections. We here attempted to address this knowledge gap, using both local data from 98 
a single hospital and data from a national audit database in the United Kingdom. 99 
Materials and Methods 100 
The design, management, and analysis of this observational cohort study were 101 
conducted according to the principles declared in The World Medical Association’s 102 
Declaration of Helsinki. All data were analysed anonymously, retrospectively, and did 103 
not impact upon the clinical care of any patients. 104 
The definitions of sepsis and systemic inflammatory response syndrome (SIRS) 105 
were based on the 2012 Surviving Sepsis Guidelines in place at that time (17). The local 106 
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data collection was approved by the South East Wales Research Ethics Committee 107 
(reference number 10WSE/421, June 2011) and registered with the UK Clinical 108 
Research Network (UKCRN; Cellular and biochemical investigations in sepsis, ID 109 
11231). 110 
The national data were screened from all admissions to NHS adult, general 111 
critical care units in England, Wales, and Northern Ireland participating in the Case Mix 112 
Programme of the Intensive Care National Audit & Research Centre (ICNARC) Data 113 
Specification between 1 January 2007 – 30 June 2012. An analysis plan was agreed a 114 
priori according to the following definitions: 115 
First-hit infection: patients admitted with a non-infective diagnosis that 116 
subsequently developed an intensive care unit-acquired infection in blood. 117 
Second-hit infection: patients admitted with severe sepsis as an initial diagnosis 118 
that subsequently developed an intensive care unit-acquired infection in blood. 119 
 All patients were categorised into those that developed Gram-positive or Gram-120 
negative infection subtypes. Four specific patient subgroups were chosen before 121 
analysis as the first-hit cohort. These sub-groups were patients categorised as having 122 
trauma, emergency neurosurgical, elective surgical, and cardiogenic shock as their 123 
primary reason for intensive care admission. It has been shown that these patients can 124 
provide a plausible and accessible model of the development of severe sepsis (18).  125 
As described above, patients in the second-hit cohort were admitted to the ICU 126 
with an initial diagnosis of severe sepsis, and then subsequently developed an intensive 127 
care unit-acquired infection in blood. Thereafter, the same descriptive statistics and 128 
survival analyses were applied to patients with first-hit and second-hit infections. Acute 129 
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hospital mortality was defined as the status at ultimate discharge from the acute 130 
hospital, excluding re-admissions within the same hospital stay. 131 
The main organism causing the first-hit infection in blood was defined as the 132 
presence of an infection in any blood sample taken for microbiological culture 48 hours 133 
or more following admission to the intensive care unit. Similarly, second-hit infection in 134 
blood was defined as the presence of infective bacteria in any blood sample taken for 135 
microbiological culture 48 hours or more following admission to the intensive care unit 136 
in patients admitted with severe sepsis as initial diagnosis. If two organisms were 137 
isolated in both blood culture bottles, first organism priority was given according to the 138 
following ranking used by ICNARC: Methicillin resistant Staphylococcus aureus 139 
(MRSA); Staphylococcus aureus (not MRSA); vancomycin resistant Enterococcus spp. 140 
(VRE); Enterococcus spp. (not VRE); yeast (e.g. Candida spp.); Pseudomonas spp.; 141 
Acinetobacter spp.; Enterobacter spp.; Klebsiella spp.; Serratia spp.; Escherichia coli; 142 
or other organisms entered using free text. The Gram classifications were then specified 143 
from the organism reported as the main organism causing first unit-acquired infection in 144 
blood. 145 
The local dataset consisted of patients admitted with severe sepsis to the 146 
intensive care unit (ICU) at The Royal Glamorgan Hospital, Llantrisant, UK between 147 
2010 and 2013 were retrospectively analysed for 90-day all-cause mortality according 148 
to the Gram status of the organism responsible for their initial sepsis diagnosis. Due to 149 
the narrow limits of this data collection restricted to electronically captured 150 
microbiological data and outcome data only, it was not possible to propensity match 151 
patients nor compare other cofounders such as age that may lead to excessive mortality 152 
in one arm of this study. 153 
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Cumulative survival curves as a function of time were generated using the 154 
Kaplan-Meier approach with censored results indicating patient discharge and compared 155 
using the log-rank test. Intergroup differences in baseline characteristics were compared 156 
using a two-Way ANOVA, unmatched and corrected for multiple comparisons with a 157 
Sidak test using SPSS 20.0. 158 
The funders had no role in study design, data collection, data analysis, data 159 
interpretation, or writing of the report.  All authors had full access to all the data in the 160 
study and share final responsibility for the decision to submit for publication. The 161 
ICNARC data is available on request directly to icnarc@icnarc.org. 162 
Results 163 
Outcomes from first-hit infections according to local and national datasets 164 
The Kaplan-Meier curve shown in Figure 1A demonstrates that when a Gram-165 
negative organism was identified as the prime cause of sepsis, patients had an excessive 166 
mortality rate of 29.1% compared with 21.3% for those where a Gram-positive 167 
organism was identified. This was equivalent to an odds ratio for death of 1.8 (1.18 – 168 
2.73) in the Gram-negative subgroup. 169 
In order to corroborate this relationship on a national scale, ICNARC’s database 170 
of UK critical care units was used. ICNARC records do not include the causative 171 
organisms responsible for admissions to ICU with severe sepsis. The only recorded 172 
organism names are those responsible for “unit-acquired infections” occurring within 72 173 
hours following admission to ICU with alternative pathologies. We therefore identified 174 
groups of patients admitted to ICU without an infective aetiology (trauma and elective 175 
surgery patients) to examine clinical outcome differences following acquisition of a 176 
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unit-acquired infection that could act as a surrogate for first-hit infection causing severe 177 
sepsis. 178 
The baseline characteristics of these groups of first-hit patients are shown in 179 
Table 1. While intergroup differences existed between trauma and elective surgery 180 
patients, as expected, the Gram-positive and Gram-negative groups within each cohort 181 
showed no significant differences in baseline parameters. Despite this similarity in 182 
morbidity, mortality rates showed striking differences between the two groups. 183 
Importantly, the mortality patterns in trauma (Fig.1B) and elective surgery patients 184 
(Fig.1C) matched that of the local dataset (Fig.1A). Mortality from Gram-negative 185 
infections in the trauma and elective groups was 27.9% and 43.6%, respectively, 186 
compared with 20.6% and 25.6% for Gram-positive infections. Overall, this translated 187 
to an odds ratio for death of 1.4 and 1.7, respectively, in trauma and elective surgery 188 
patients with Gram-negative infections. No significant differences were found in the 189 
mortality of patients with cardiogenic shock and those undergoing emergency 190 
neurosurgery although the numbers in these sub-groups were low. (Suppl. Fig.1). 191 
National outcomes from second-hit infections 192 
As ICNARC records unit-acquired organism names in different cohorts of 193 
patient groups, it was possible to examine the mortality in severe sepsis patients who 194 
develop a second-hit infection. The baseline characteristics of these patients had no 195 
statistical differences when using Gram status as a comparator (Table 1). However, 196 
compared with first-hit infections, an inverse relationship between Gram status and 197 
mortality was seen. Second-hit infections in sepsis patients had a mortality of 40.4% 198 
when a Gram-negative infection was responsible compared with 43.6% when Gram-199 
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positive organisms were recorded (Fig.1D). This resulted in an odds ratio for death of 200 
0.8 following infection with Gram-negative pathogens in second-hit infections. 201 
 202 
Discussion 203 
The present analysis accords with previous studies showing that first-hit 204 
infections caused by Gram-negative organisms result in a greater mortality in sepsis 205 
compared with Gram-positive pathogens (12). In striking contrast to this pattern in 206 
primary infections, our findings are the first to show that Gram-positive second-hit 207 
infections carry a higher risk of death compared to infections caused by Gram-negative 208 
pathogens. Of note, the national scale and standardised reporting of the corresponding 209 
data provide a significant advance in the analysis of differential outcomes in well-210 
defined subgroups of patients developing first-hit or second-hit sepsis, that can now be 211 
addressed further in the clinic and experimentally.  212 
Although infection-related organ dysfunction continues to be responsible for 213 
approximately 30% of ICU admissions, there is a surprising lack of comparative 214 
epidemiological data on the recent trends of infective organisms. The largest such 215 
dataset to-date, the EPIC II study, is almost 10 years old (11). In that study, the 216 
investigators found a larger prevalence of Gram-negative infections and worse 217 
outcomes associated with certain organisms, and observed a significant relationship 218 
between time spent on the ICU and development of infections, particularly those caused 219 
by methicillin-resistant S. aureus (MRSA), Acinetobacter and Pseudomonas species 220 
(11). A small-scale study from mainland China recently confirmed this distribution of 221 
the infective organisms (16). Our present findings demonstrate that the relative risk 222 
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attributable to Gram-negative compared with Gram-positive mortality may be as high as 223 
1.7 for first-hit infections.  224 
The underlying causes for these mortality differences are likely to be 225 
multifactorial. Firstly, there may be logistical and procedural reasons as to why these 226 
patients have an excessive mortality. The increasing levels of multidrug-resistant Gram-227 
negative organisms (17,18) may render patients with these causative organisms more 228 
likely to receive ineffective initial therapy (19,20). However, recent data from the 229 
World Healthcare-Associated Infections Forum indicates that multidrug-resistant Gram-230 
negative organisms only play a very small role in the UK with incidences below 5%, 231 
making this explanation less plausible (21).  232 
Secondly, there may be unmeasured pathological differences due to the 233 
epidemiology of different organisms. In fact, after adjustments for organism class and 234 
type, the site of infection appears to play a key role in differential patient survival 235 
(10,21,22). With the knowledge that patterns of microbial classes differ between 236 
different infectious sources, simply basing a mortality prediction on an organism type 237 
may act as a surrogate for the likely source of infection. This may help explain some of 238 
the variation shown in the literature comparing organism class and species. The extent 239 
of variation shown in those studies exposes many of the difficulties inherent in 240 
retrospective analysis of a syndrome characterised by a number of individual disease 241 
entities across a hugely variable cohort of patients. In conjunction with widely varying 242 
microbial resistance patterns across different countries, the inconsistent use and timing 243 
of appropriate antibiotics makes comparing international results a difficult task and 244 
further highlights the need for better quality data. 245 
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Thirdly, the differences in outcome between Gram-negative and Gram-positive 246 
infections may represent a particular predisposition of different patients to develop 247 
distinct types of infections (16,23-26). What has been observed in our study may simply 248 
be an excessive mortality due to genetic and environmental differences rather than the 249 
microorganisms directly. However, despite these possibilities, it is undeniable that the 250 
Gram status can be used as a strong signal to point towards an expected excessive 251 
mortality. This in itself is important and useful. 252 
Finally, there are clear immunological differences that occur as a result of an 253 
organism’s structural and biochemical characteristics. As a classical example, this may 254 
predominantly be due to the presence of a lipopolysaccharide (LPS)-containing cell wall 255 
in Gram-negative bacteria. LPS is recognised by a range of cell types and promotes 256 
inflammation as well as acts as potent inducer of the coagulation cascade (27). In 257 
addition to the presence of LPS as a major discriminator between Gram-negative and 258 
Gram-positive bacteria, such mortality differences seen here may also be influenced by 259 
other pathogen-specific characteristics including the ability of most Gram-negative 260 
organisms to activate innate-like Vγ9/Vδ2 T cells and mucosal-associated invariant T 261 
(MAIT) cells (28,29). Individual organism pathogenicity will also influence patient 262 
outcomes as much as the pharmacokinetics of the drugs used to target such microbes. 263 
Therefore, more virulent Gram-negative microbes may more rapidly replicate and have 264 
higher toxin loads (30).  265 
What is more intriguing than the relationship between Gram status and mortality 266 
from first-hit infection is the apparent inverse relationship between mortality and Gram 267 
status in sepsis patients who subsequently acquire a second-hit infection. Again, this is 268 
likely to be multifactorial. There is a wealth of immunological literature demonstrating 269 
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profound reprogramming effects on both cellular and humoral immunity that severe 270 
sepsis leaves in its wake (23-26,28,31,32). These tolerising effects may render survivors 271 
of first-hit infections more resistant to subsequent Gram-negative sepsis. There may 272 
also be organisational aspects to these mortality differences including the use of 273 
antimicrobials with adverse side effect profiles in Gram-positive second-hit infections 274 
to cover the possibility of MRSA infection. Furthermore, there may be a survival bias to 275 
these data. For example, those patients who survive an initial Gram-negative infection 276 
may have an inherent resistance to Gram-negative infections. Therefore, these patients 277 
may be more likely to survive and subsequently develop second-hit infections, and the 278 
data might thus be skewed towards a survival benefit of Gram-negative infection when 279 
these patients develop a second infection.  280 
Several improvements could be made in future studies of this topic. Firstly, 281 
microbiological data on true first-hit sepsis patients were not available through 282 
ICNARC’s dataset. Therefore, we defined surrogate first-hit infection subgroups 283 
including post-operative elective surgery and trauma patients. There is a large volume 284 
of research supporting the use of these groups of patient’s as a model for investigating 285 
first-hit infection(18). With the advent of new nation-wide systems of sepsis outcomes 286 
such as the recording through the work of the UK Sepsis Trust and the National Institute 287 
for Health and Care Excellence (NICE), causative organism data may be possible to 288 
analyse in the future. Indeed, new trial design may be a key component of improving 289 
research in this area (3). Studies should also aim to address the survival bias discussed 290 
above. By recording the initial infecting organism responsible for the first-hit sepsis, it 291 
should be possible to explore such relationships further. 292 
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Secondly, although the ICNARC dataset has considerable power due to its size 293 
and robust collection methods, it suffers from lack of granular detail and a relatively 294 
arbitrary collection priority of organisms. It would be important in future research to 295 
record when and from where individual organisms are isolated. The ranking of 296 
organisms allowing only a single species to be recorded may bias data collection in 297 
favour of Gram-positive infections that in turn may skew future analysis. The list of 298 
organisms was based on data from the European Centre for Disease Prevention and 299 
Control for the UK and has been shown to be representative in independent datasets 300 
(33). Therefore, ICNARC outcome data have significant clinical relevance in everyday 301 
practice.  In addition to these possible confounders, the disease severity scores in the 302 
present study were recorded at the time of ICU admission, rather than at the time of 303 
initial pathology (i.e. surgical procedure time point), and may thus have diverged by the 304 
time of subsequent ICU admission. Unfortunately, the ICNARC dataset is not able to 305 
compensate for these factors. However, despite these methodical issues, they remain 306 
constant in all groups studied and as such cannot account for the reversal of mortality in 307 
first-hit compared with second-hit infections. This is a clear signal being sent although 308 
the intricacies of this detail will need to be addressed with a different future 309 
methodology. 310 
Conclusion 311 
Overall, our study demonstrates that Gram-negative infections are associated with a 312 
greatly elevated mortality in first-hit sepsis patients whilst these differences are reversed 313 
in second-hit infections. These findings will allow clinicians to better plan and deliver 314 
care to the patients most at risk from severe sepsis by targeting resources more 315 
effectively. It may also form a platform to explore the immune reprogramming effects 316 
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of sepsis ex vivo by comparing subsequent responses from patients with differing initial 317 
infection types. 318 
Acknowledgements 319 
The work described received support from the UK Clinical Research Network Study 320 
Portfolio, SARTRE/SEWAHSP Health Technology Challenge Scheme and MRC 321 
Confidence in Concept scheme.  TS was in receipt of a Clinical Research Fellowship 322 
from the National Institute of Social and Health Care Research (NISCHR). 323 
Prov
ision
al
 16 
References 
1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes 
of death in children. The Lancet. 2005 Mar;365(9465):1147–52.  
2. Newton S, Cunningham J, Dobbin J. Sepsis and the NHS. All-Party 
Parliamentary Group on Sepsis.  
3. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two 
Decades of Mortality Trends Among Patients With Severe Sepsis. Critical Care 
Medicine. 2014 Mar;42(3):625–31.  
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 
Epidemiology of severe sepsis in the United States: analysis of incidence, 
outcome, and associated costs of care. Critical Care Medicine. 2001 
Jul;29(7):1303–10.  
5. Schmid A, Burchardi H, Clouth J, Schneider H. Burden of illness imposed by 
severe sepsis in Germany. Eur J Health Econ. 2002;3(2):77–82.  
6. Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day AG. A long-
term follow-up study investigating health-related quality of life and resource 
use in survivors of severe sepsis: comparison of recombinant human activated 
protein C with standard care. Crit Care. 2007;11(6):R128.  
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. 
Definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. 
American College of Chest Physicians/Society of Critical Care Medicine. 
1992. pp. 1644–55.  
8. Opal SM, Cohen J. Clinical gram-positive sepsis: does it fundamentally differ 
from gram-negative bacterial sepsis? Critical Care Medicine. 1999 
Aug;27(8):1608–16.  
9. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. 
International study of the prevalence and outcomes of infection in intensive 
care units. JAMA. 2009 Dec 2;302(21):2323–9.  
10. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. 
Sepsis in European intensive care units: results of the SOAP study. Critical 
Care Medicine. 2006 Feb;34(2):344–53.  
11. Labelle A, Juang P, Reichley R, Micek S, Hoffmann J, Hoban A, et al. The 
determinants of hospital mortality among patients with septic shock receiving 
appropriate initial antibiotic treatment. Critical Care Medicine. 2012 
Jul;40(7):2016–21.  
12. Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB. Variations in 
organism-specific severe sepsis mortality in the United States: 1999-2008. 
Critical Care Medicine. 2015 Jan;43(1):65–77.  
P v
i i
al
 17 
13. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. 
Impact of time to antibiotics on survival in patients with severe sepsis or septic 
shock in whom early goal-directed therapy was initiated in the emergency 
department. Critical Care Medicine. 2010 Apr;38(4):1045–53.  
14. McPherson D, Griffiths C, Williams M, Baker A, Klodawski E, Jacobson B, et 
al. Sepsis-associated mortality in England: an analysis of multiple cause of 
death data from 2001 to 2010. BMJ Open. 2013;3(8).  
15. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, 
et al. The prevalence of nosocomial infection in intensive care units in Europe. 
Results of the European Prevalence of Infection in Intensive Care (EPIC) 
Study. EPIC International Advisory Committee. JAMA. 1995 
Aug;274(8):639–44.  
16. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. 
Human Toll-Like Receptor 4 Mutations but Not CD14 Polymorphisms Are 
Associated with an Increased Risk of Gram-Negative Infections. Journal of 
Infectious Diseases. 2002 Nov 15;186(10):1522–5.  
17. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. 
Surviving sepsis campaign: international guidelines for management of severe 
sepsis and septic shock: 2012. 2013. pp. 580–637.  
18. Cain DJ, del Arroyo AG, Ackland GL. Man is the new mouse: Elective surgery 
as a key translational model for multi-organ dysfunction and sepsis. Journal of 
the Intensive Care Society. 2015 May 1;16(2):154–63.  
19. Micek S, Johnson MT, Reichley R, Kollef MH. An institutional perspective on 
the impact of recent antibiotic exposure on length of stay and hospital costs for 
patients with gram-negative sepsis. BMC Infect Dis. 2012;12:56.  
20. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. 
Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in 
Gram-negative severe sepsis and septic shock: a retrospective cohort study. 
Crit Care. 2014;18(6):596.  
21. Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A. 
Association between Source of Infection and Hospital Mortality in Patients 
Who Have Septic Shock. American Journal of Respiratory and Critical Care 
Medicine. 2014 May 15;189(10):1204–13.  
22. De Waele J, Lipman J, Sakr Y, Marshall JC, Vanhems P, Barrera Groba C, et 
al. Abdominal infections in the intensive care unit: characteristics, treatment 
and determinants of outcome. BMC Infect Dis. 2014;14:420.  
23. Cavaillon J-M, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance 
as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10(5):233.  
24. Escoll P, del Fresno C, Garcı́a L, Vallés G, Lendı́nez MJ, Arnalich F, et al. 
Rapid up-regulation of IRAK-M expression following a second endotoxin 
challenge in human monocytes and in monocytes isolated from septic patients. 
P o
is on
al
 18 
Biochemical and Biophysical Research Communications. 2003 
Nov;311(2):465–72.  
25. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance 
and M2 (alternative) macrophage polarization are related processes 
orchestrated by p50 nuclear factor κB. Proceedings of the National Academy of 
Sciences. National Acad Sciences; 2009;106(35):14978–83.  
26. Lynn LA. The diagnosis of sepsis revisited - a challenge for young medical 
scientists in the 21st century. Patient Saf Surg. 2014;8(1):1.  
27. Mansur A, Gruben von L, Popov AF, Steinau M, Bergmann I, Ross D, et al. 
The regulatory toll-like receptor 4 genetic polymorphism rs11536889 is 
associated with renal, coagulation and hepatic organ failure in sepsis patients. J 
Transl Med. 2014;12:177.  
28. Davey MS, Morgan MP, Liuzzi AR, Tyler CJ, Khan MWA, Szakmany T, et al. 
Microbe-specific unconventional T cells induce human neutrophil 
differentiation into antigen cross-presenting cells. The Journal of Immunology. 
2014 Oct 1;193(7):3704–16.  
29. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaaz F, et 
al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically 
ill patients with severe infections. Intensive Care Med. 2014 Feb;40(2):192–
201.  
30. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: 
a brief review. virulence. 2014 Jan 1;5(1):213–8.  
31. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and 
economic implications of combining drugs and clinical biomarkers. Nat Rev 
Drug Discov. 2007 Apr;6(4):287–93.  
32. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel 
understanding of the disorder and a new therapeutic approach. The Lancet 
Infectious Diseases. 2013 Mar;13(3):260–8.  
 
  
Prov
isio
al
 19 
Contributors 
MM, KR and ME designed the study.  TS and PO abstracted the local data.  SP and 
KR abstracted the national data from the Case Mix Programme.  MM, SP and KR 
directed and conducted the data analysis.  MM, TS and ME wrote the paper.  JH 
provided expert advice and revised the draft.  All authors read and approved the final 
version. 
Funding 
Dr. Szakmany reports grants from National Institute of Social and Health Care 
Research, Welsh Assembly Government, UK, during the conduct of the study. 
Dr Eberl reports grants from SARTRE/SEWAHSP Health Technology Challenge and 
the MRC Confidence in Concept scheme, during the conduct of the study. 
  
Prov
ision
al
 20 
Table 1 Baseline patient characteristics from the ICNARC dataset according to 
infecting organism type.
 
There were no significant differences in these baseline characteristics between 
organism types within respective groups to explain the mortality differences observed 
by Gram-status. The results were analysed using a Two-Way ANOVA, unmatched 
 First-hit (trauma) First-hit (elective surgery) Second-hit 
 Gram + Gram − Gram + Gram − Gram + Gram − 
Number of 
admissions % [N] 49.8 [353] 49.4 [350]  46.4 [308]  53.2 [308]  47.3 [1,009]  52.1 [1,110]  
Age mean (sd) 48.6 (20.0) 49.5 (19.8) 64.4 (14.6) 67.6 (12.8) 61.9 (14.9) 61.6 (15.4) 
Gender % male 77.9 74.9 69.2 76.8 60.5 59.4 
Caucasian % 88.6 90.6 95.6 96.9 94.0 92.4 
Liver condition in 
PMH % 1.1 1.1 2.0 4.0 48.6 47.8 
Renal condition in 
PMH % 0.0 1.7 0.0 2.0 1.7 1.6 
Respiratory 
condition in PMH % 0.6 0.6 1.0 4.0 48.4 47.5 
Cardiovascular 
condition in PMH % 0.3 0.3 2.0 4.0 0.9 0.8 
In- hospital CPR % 0.8 4.0 2.0 3.0 3.1 2.3 
Community CPR % 0.0 2.0 0.0 0.0 0.3 0.4 
No CPR % 97.2 94.0 98.3 97.9 96.6 97.3 
ICNARC mean (sd) 19.4 (6.7) 20.9 (7.2) 18.2 (8.3) 17.8 (7.3) 25.2 (8.1) 25.5 (8.1) 
APACHE II mean 
(sd) 14.5 (6.2) 14.9 (6.7) 16.5 (5.8) 16.2 (4.7) 20.4 (6.3) 20.3 (6.5) 
Acute hospital 
mortality % 20.6 27.9 ** 25.6 43.6 ** 46.3 40.4 ** 
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and corrected for multiple comparisons with a Sidak test. p < 0.05 *, p < 0.01 **, p < 
0.001 ***. PMH, past medical history; CPR, cardiopulmonary resuscitation; 
APACHE, Acute Physiology And Chronic Health Evaluation. 
 
Figure 1. Kaplan-Meier analysis of sepsis patient survival according to Gram 
status of the causative organism. (A) Local dataset of first-hit sepsis patients 
(n=350). (B) ICNARC dataset of first-hit trauma patients developing a unit-acquired 
infection (n=703). (C) ICNARC dataset of first-hit elective surgery patients 
developing a unit-acquired infection (n=616). (D) ICNARC dataset of second-hit 
sepsis patients subsequently developing a unit-acquired infection (n=2131). All Gram 
differences are significant using the Mantel-Cox (Log-rank) test at p < 0.01. 
 
Supplementary figure. Kaplan-Meier analysis of sepsis patient survival 
according to Gram status of the causative organism. (A) ICNARC dataset of first-
hit emergency neurosurgical patients developing a unit-acquired infection (n=104). 
(B) ICNARC dataset of first-hit cardiogenic shock patients developing a unit-acquired 
infection (n=56).  None of the Gram differences are significant using the Mantel-Cox 
(Log-rank) test at p < 0.05. 
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